Biomedical Systems Announces Vice President, Imaging Services
Biomedical Systems, a global provider of centralized diagnostic testing for the pharmaceutical and medical device industry, recently announced the promotion of Sam Dranoff to Vice Present of Business Development, Imaging Services.
Biomedical Systems Announces Vice President, Imaging Services
August 27, 2008 – St. Louis, MO – Biomedical Systems, a global leader in centralized diagnostic testing for the pharmaceutical and medical device industry, recently announced the promotion of Sam Dranoff to Vice Present of Business Development, Imaging Services. Dranoff will continue with his current responsibilities while growing a team of global business development directors for Biomedical Systems, Imaging Services. The business unit has experienced significant growth since Dranoff joined the division in 2005, and most recently served as Managing Director, Commercial Operations.
"We have grown the imaging business to a point where we see a need for expanding the Business Development team. Sam has the proven experience and talent to grow and manage this team as well as the vision to see it succeed. That is why I'm so excited that he has accepted this new position and I'm confident that he will add great value in his new role." said Jesse Bowden, President of Imaging Services, Biomedical Systems.
Biomedical Systems is a fully digital imaging core lab that supports clinical trials in dozens of therapeutic categories. Leveraging combined corporate resources that includes ECG core lab and respiratory core lab, Biomedical Imaging Services provides sponsors unmatched diagnostic service offerings on a global basis.
Biomedical Systems is a global provider of centralized diagnostic services for the pharmaceutical and medical device industries. With offices in North America, Europe and Asia, Biomedical Systems has worked with over 11,000 investigative sites in 75 countries around the world for Phase I - IV clinical trials. Biomedical Systems centralized services include the acquisition, analysis and management of data for Cardiac, Imaging and Respiratory modalities used to determine safety and efficacy for drugs and devices in clinical trials. For more information about Biomedical Systems, please contact Traci Cardenas, Marketing Manager at 1-800-877-6334 (3338) or via email, tcardenas@biomedsys.com. Additional information can be found on the company website at www.biomedsys.com.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
